TITLE

EURAND IN-LICENSES NOVEL ANALGESICS

PUB. DATE
March 2006
SOURCE
Worldwide Biotech;Mar2006, Vol. 18 Issue 3, p8
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Reports that specialty pharmaceutical company Eurand has signed research agreements with two Universities in Italy to evaluate a class of analgesic compounds. Expectation on the class of analgesic compounds; Terms of the agreement; Comments from company CEO Gearoid Faherty on the research agreement.
ACCESSION #
20451869

 

Related Articles

  • WEEK IN REVIEW.  // BioWorld Insight;9/7/2009, Vol. 17 Issue 36, p6 

    The article offers news related to biotechnology financings and deals in the U.S. It relates that Eurand NV has obtained approval of its Zenpep (pancrelipase) delayed-release capsules from the Food and Drug Administration (FDA). It mentions that Algeta ASA has received an 800 million dollars...

  • Hired Education. Washburn, Jennifer // American Prospect;Feb2005, Vol. 16 Issue 2, p29 

    Discusses the increasing number of universities in the U.S. that look and behave like business enterprises in efforts to become research branches of private industry, as of February 2005. Factors that led to the redefinition of the mission of universities; Significance of publicly funded...

  • Crunch time for pharma. Martin, John // New Scientist;10/10/2009, Vol. 204 Issue 2729, p24 

    The author reflects on the implications of financial crises for pharmaceutical research. He says that while big pharmaceutical companies have much money, universities are being starved of resources and research funding has decreased. He asserts that the tax system could at least encourage...

  • Taking after the Tigers. Field, Alan M. // Journal of Commerce (1542-3867);2/13/2006, Vol. 7 Issue 7, p16 

    This article provides information on a new research consortium called the African Biotherapeutics Institute which aims to develop the vast potential of Africa for biodiversity-based, value-added products, including pharmaceuticals and nutritional products. The consortium will bring together...

  • FDA APPROVALS IN AUGUST.  // BioWorld Insight;9/14/2009, Vol. 17 Issue 37, p7 

    The article presents the pharmaceutical companies in the U.S. with their medicines and indications which received the approval from the Food and Drug Administration (FDA) in August 2009 which include Kowa Pharmaceuticals America Inc., Eurand NV, Janssen Pharmaceutica NV and King Pharmaceuticals Inc.

  • The determinants of pharmaceutical research and development expenditures. Grabowski, Henry; Vernon, John // Journal of Evolutionary Economics;2000, Vol. 10 Issue 1/2, p201 

    Abstract. Since the late 1970s, pharmaceutical R&D has grown at a rapid rate relative to sales and other variables. In this paper, we examine the determinants of pharmaceutical R&D using a pooled data sample of 11 major drug firms over the period 1974 to 1994. We find that expected returns and...

  • Prescription marketing. Tyndale-Biscoe, Julian // Marketing (00253650);8/7/2003, p20 

    Trying to reach consumers is a hard task for drug companies in Great Britain. Pharmaceutical companies are not only facing increased competition and regulatory hurdles, but also a drop in research and development and downward price pressure. Research and development is one key battlefield....

  • Legal Pains from Super Painkiller.  // Perspective (08889732);May2004, Vol. 19 Issue 5, p5 

    Reports that the federal appeals court has upheld the dismissal of a lawsuit brought by the University of Rochester (UR), New York. Effort of the school to stop a major pharmaceutical company from using a UR patent to make the painkiller drug Celebrex; Claims of the UR; Injunction to halt...

  • Eurand completes EU registration procedure for paracetamol ODT tablets.  // PharmaWatch: CNS;Sep2009, Vol. 8 Issue 9, p21 

    The article reports that Eurand NV completed the registration of 250 and 500 milligrams (mg) paracetamol orodispersible tablets (ODT) in European Union (EU) countries. It notes that paracetamol is a widely utilized analgesic and paracetamol ODT is for treating mild-to moderate pain. It states...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics